IJU case reports · 2026
Essential Renal Bleeding Presenting as Persistent Unilateral Hematuria Successfully Treated With Factor XIII Replacement Therapy: A Case Report.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toyoshima Moe, Maekawa Shigekatsu, Machida Arisa, Sekiguchi Kie, Ikarashi Daiki, Kato Renpei, Kanehira Mitsugu, Sugimura Jun, Obara Wataru
Аннотация
INTRODUCTION: Essential renal bleeding is rare and lacks standardized treatment; organ-preserving options are critical in older patients with impaired renal function.
CASE PRESENTATION: A woman in her early 80s with atrial fibrillation treated with edoxaban, chronic heart failure, and advanced chronic kidney disease presented with gross hematuria and bladder tamponade. Bleeding was localized to the right renal pelvis and ureter, with no tumor, urolithiasis, vascular malformation, or glomerular disease; essential renal bleeding was diagnosed. Hematuria persisted despite edoxaban discontinuation, red blood cell and plasma transfusions, and carbazochrome sodium sulfonate administration. Isolated factor XIII activity was 22%. Intravenous plasma-derived factor XIII concentrate achieved sustained hemostasis, renal function remained stable, and reduced-dose edoxaban was safely resumed. Hematuria did not recur within 24 months.
CONCLUSION: In this population, factor XIII deficiency may contribute to persistent unilateral hematuria despite normal conventional coagulation tests.
CASE PRESENTATION: A woman in her early 80s with atrial fibrillation treated with edoxaban, chronic heart failure, and advanced chronic kidney disease presented with gross hematuria and bladder tamponade. Bleeding was localized to the right renal pelvis and ureter, with no tumor, urolithiasis, vascular malformation, or glomerular disease; essential renal bleeding was diagnosed. Hematuria persisted despite edoxaban discontinuation, red blood cell and plasma transfusions, and carbazochrome sodium sulfonate administration. Isolated factor XIII activity was 22%. Intravenous plasma-derived factor XIII concentrate achieved sustained hemostasis, renal function remained stable, and reduced-dose edoxaban was safely resumed. Hematuria did not recur within 24 months.
CONCLUSION: In this population, factor XIII deficiency may contribute to persistent unilateral hematuria despite normal conventional coagulation tests.